Implementing lessons learned from previous bronchial biopsy trials in a new randomized controlled COPD biopsy trial with roflumilast

BMC Pulmonary Medicine

Volumn 14, Issue 1, 2014, Pages

  Barnes, Neil C ^a,b   Saetta, Marina ^c   Rabe, Klaus F ^d,e  

^a GLAXOSMITHKLINE   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF PADOVA   (Italy)

^d Germany and LungenClinic Grosshansdorf ^*  (Germany)

^e UNIVERSITY OF KIEL   (Germany)

Author keywords

Bronchial biopsy; Bronchoscopy; Chronic obstructive pulmonary disease; Exacerbation; Histology; Inflammation; Protocol; Roflumilast; Sputum

Indexed keywords

AMINOPYRIDINES; BENZAMIDES; BIOLOGICAL MARKERS; BIOPSY; CYCLOPROPANES; DOUBLE-BLIND METHOD; HUMANS; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84893160403     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-14-9     Document Type: Article

References (34)

1. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, Schmid V, Buist S. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006, 27:397-412. 10.1183/09031936.06.00025805, 16452599.
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD. 2011, Available from: http://www.goldcopd.org.
3. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:2645-2653. 10.1056/NEJMoa032158, 15215480.
4. O'Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997, 155:852-857. 10.1164/ajrccm.155.3.9117016, 9117016.
5. Lacoste JY, Bousquet J, Chanez P, Van VT, Simony-Lafontaine J, Lequeu N, Vic P, Enander I, Godard P, Michel FB. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol 1993, 92:537-548. 10.1016/0091-6749(93)90078-T, 8409114.
6. Saetta M, Turato G, Facchini FM, Corbino L, Lucchini RE, Casoni G, Maestrelli P, Mapp CE, Ciaccia A, Fabbri LM. Inflammatory cells in the bronchial glands of smokers with chronic bronchitis. Am J Respir Crit Care Med 1997, 156:1633-1639. 10.1164/ajrccm.156.5.9701081, 9372687.
7. Saetta M, Di SA, Turato G, Facchini FM, Corbino L, Mapp CE, Maestrelli P, Ciaccia A, Fabbri LM. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157:822-826. 10.1164/ajrccm.157.3.9709027, 9517597.
8. Saetta M, Baraldo S, Corbino L, Turato G, Braccioni F, Rea F, Cavallesco G, Tropeano G, Mapp CE, Maestrelli P, et al. CD8 + ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 160:711-717. 10.1164/ajrccm.160.2.9812020, 10430750.
9. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, Fabbri LM, Johnston SL. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006, 173:1114-1121. 10.1164/rccm.200506-859OC, 16484677.
10. Perera WR, Hurst JR, Wilkinson TM, Sapsford RJ, Mullerova H, Donaldson GC, Wedzicha JA. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007, 29:527-534. 10.1183/09031936.00092506, 17107990.
11. Qiu Y, Zhu J, Bandi V, Atmar RL, Hattotuwa K, Guntupalli KK, Jeffery PK. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 168:968-975. 10.1164/rccm.200208-794OC, 12857718.
12. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000, 55:114-120. 10.1136/thorax.55.2.114, 1745686, 10639527.
13. Makris D, Lazarou S, Alexandrakis M, Kourelis TV, Tzanakis N, Kyriakou D, Gourgoulianis KI. Tc2 response at the onset of COPD exacerbations. Chest 2008, 134:483-488. 10.1378/chest.07-2626, 18490406.
14. Tsoumakidou M, Tzanakis N, Chrysofakis G, Kyriakou D, Siafakas NM. Changes in sputum T-lymphocyte subpopulations at the onset of severe exacerbations of chronic obstructive pulmonary disease. Respir Med 2005, 99:572-579. 10.1016/j.rmed.2004.10.005, 15823454.
15. Mallia P, Message SD, Contoli M, Gray K, Telcian A, Laza-Stanca V, Papi A, Stanciu LA, Elkin S, Kon OM, et al. Lymphocyte subsets in experimental rhinovirus infection in chronic obstructive pulmonary disease. Respir Med 2013, 108:78-85.
16. Bourbeau J, Christodoulopoulos P, Maltais F, Yamauchi Y, Olivenstein R, Hamid Q. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007, 62:938-943. 10.1136/thx.2006.071068, 2117108, 17557771.
17. Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, Zhu J, Johnson M, Thomson NC, Jeffery PK. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006, 173:736-743. 10.1164/rccm.200508-1321OC, 16424444.
18. Lapperre TS, Snoeck-Stroband JB, Gosman MM, Jansen DF, van Schadewijk S, Thiadens HA, Vonk JM, Boezen HM, Ten Hacken NH, Sont JK, et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2009, 151:517-527. 10.7326/0003-4819-151-8-200910200-00004, 19841453.
19. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374:685-694. 10.1016/S0140-6736(09)61255-1, 19716960.
20. Rennard SI, Calverley PM, Goehring UM, Bredenbroker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD. Respir Res 2011, 12:18. 3040135, 21272339.
21. Grootendorst DC, Gauw SA, Verhoosel RM, Sterk PJ, Hospers JJ, Bredenbroker D, Bethke TD, Hiemstra PS, Rabe KF. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007, 62:1081-1087. 10.1136/thx.2006.075937, 2094292, 17573446.
22. Hattotuwa K, Gizycki MJ, Ansari TW, Jeffrey PK, Barnes NC. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease. A double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002, 165:1592-1596. 10.1164/rccm.2105025, 12070058.
23. Gamble E, Grootendorst DC, Brightling CE, Troy S, Qiu Y, Zhu J, Parker D, Matin D, Majumdar S, Vignola AM, et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 168:976-982. 10.1164/rccm.200212-1490OC, 12816740.
24. Summary and recommendations of a workshop on the investigative use of fiberoptic bronchoscopy and bronchoalveolar lavage in asthmatics. Am Rev Respir Dis 1985, 132:180-182.
25. Jeffery P, Holgate S, Wenzel S. Methods for the assessment of endobronchial biopsies in clinical research: application to studies of pathogenesis and the effects of treatment. Am J Respir Crit Care Med 2003, 168:S1-S17. 10.1164/rccm.200202-150WS, 14555461.
26. Saetta M, Turato G, Baraldo S, Zanin A, Braccioni F, Mapp CE, Maestrelli P, Cavallesco G, Papi A, Fabbri LM. Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation. Am J Respir Crit Care Med 2000, 161:1016-1021. 10.1164/ajrccm.161.3.9907080, 10712357.
27. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al. Standardisation of spirometry. Eur Respir J 2005, 26:319-338. 10.1183/09031936.05.00034805, 16055882.
28. Gamble E, Burns W, Zhu J, Ansari T, De RV, Kips J, Barnes NC, Jeffery PK. Variation of CD8+ T-lymphocytes around the bronchial internal perimeter in chronic bronchitis. Eur Respir J 2003, 22:992-995. 10.1183/09031936.03.00115302, 14680091.
29. Gamble E, Qiu Y, Wang D, Zhu J, Vignola AM, Kroegel C, Morell F, Hansel TT, Pavord ID, Rabe KF, et al. Variability of bronchial inflammation in chronic obstructive pulmonary disease: implications for study design. Eur Respir J 2006, 27:293-299. 10.1183/09031936.06.00027705, 16452583.
30. Rabe KF, Bateman ED, O'donnell D, Witte S, Bredenbroker D, Bethke TD. Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005, 366:563-571. 10.1016/S0140-6736(05)67100-0, 16099292.
31. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 176:154-161. 10.1164/rccm.200610-1563OC, 17463412.
32. Hattotuwa K, Gamble EA, O'Shaughnessy T, Jeffery PK, Barnes NC. Safety of bronchoscopy, biopsy, and BAL in research patients with COPD. Chest 2002, 122:1909-1912. 10.1378/chest.122.6.1909, 12475825.
33. American Thoracic Society. Fiberoptic bronchoscopy. Patient information series. Am J Respir Crit Care Med 2004, 169:P1-P2.
34. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009, 374:695-703. 10.1016/S0140-6736(09)61252-6, 19716961.